Copper 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide complex (CuHQTS) is a copper complex with strong anticancer activity against cisplatin-resistant neuroblastoma and prostate cancer cells in vitro by cell proliferation assay or fluorescent microscopic imaging. This study aimed to evaluate anti-prostate cancer activity of CuHQTS in vivo by bioluminescence imaging (BLI) and tumor size measurement, using athymic nu/nu mice implanted with prostate cancer cells carrying luciferase reporter gene (Luc-PC3). Growth of Luc-PC3 cells (1 × 10 5 cells) implanted in athymic nu/nu mice treated with CuHQTS for 2 weeks was suppressed by measurement of luciferase signals (6.18 × 10 7 to 5.36 × 10 7 p/s/cm 2 /sr) with BLI, compared with luciferase signals of Luc-PC3 cells (4.66 × 10 7 to 1.51 × 10 8 p/s/cm 2 /sr, p < 0.05) in the mice treated with normal saline of placebo control. Moreover, the size of PC-3 xenograft tumor (126.5 ± 34.2 mm 3 ) in athymic nu/nu mice treated with CuHQTS was significantly smaller than the size of PC-3 xenograft tumor (218.6 ± 48.0 mm 3 , p < 0.05) in athymic nu/nu mice treated with normal saline of placebo control, suggesting in vivo tumor growth inhibition activity of CuHQTS on prostate cancer. The findings of this study support further investigation of CuHQTS as a promising new anticancer agent for the treatment of metastatic prostate cancer refractory to anticancer drugs currently available.
Introduction
Prostate cancer is one of the leading causes of death in men worldwide [1, 2] . Effective drugs are urgently needed for treatment of the patients diagnosed with metastatic prostate cancer refractory to therapies currently available. Cisplatin is a potent metallotherapeutic drug, but clinical application of cisplatin for treatment of prostate cancer is limited by side effects and acquired cisplatin resistance of metastatic prostate cancer [3] [4] [5] [6] . In addition to synthesizing and testing new organic molecules or compounds for anti-prostate cancer activities, there are continued efforts to develop new metallotherapeutic drugs for treatment of patients suffered from metastatic prostate cancer that are resistant to cisplatin or other anticancer drugs currently available [7] [8] [9] .
Strong anticancer activity of many copper complexes was reported early since 1960s [10, 11] . Copper-pyrrolidine dithiocarbamate complexes [Cu(PDTC) 2 , Fig. 1 ] suppressed proliferation of cisplatin-resistant BE2C human neuroblastoma cells with an IC 50 of 8.0 µM, compared to cisplatin IC 50 of 80 µM [12] . Based on Schiff-base copper coordination to form copper complex, copper complexes of 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide (CuHQTS, Fig. 1 ) and 8-hydroxyquinoline-2-carboxaldehyde-4,4-dimethyl-3-thiosemicarbazide (CuHQDMTS, Fig. 1 ) were synthesized, which showed strong anticancer activity on cisplatin-resistant neuroblastoma cells [13] . Many of copper anticancer complexes containing S, N, O-Donor system, Schiff base system, polydentate or macrocyclic system, and/ or N-N diimine system were cytotoxic against prostate cancer cells or cells of other types of cancer [14, 15] . Recently, anti-prostate cancer activity of CuHQTS and CuHQDMTS was demonstrated in vitro by Cell Counting Kits-8 (CCK8) assay and fluorescent microscopic imaging [16] . The findings suggest that CuHQTS and CuHQDMTS are promising anticancer drugs for treatment of prostate cancer refractory to cisplatin chemotherapy.
The purpose of this study was to test anti-prostate cancer activity of CuHQTS in vivo by treatment of mice implanted with prostate cancer cells with CuHQTS, using Bioluminescence Imaging (BLI). Tumor growth inhibition activity of CuHQTS in vivo was assessed by comparing the size of xenograft prostate tumor in mice treated with CuHQTS with the size of xenograft tumor in mice treated with normal saline (placebo control). The data from this study are expected to provide useful information for further study of potential application of CuHQTS for treatment of metastatic prostate cancer in humans.
Materials and methods

Chemicals, reagents, and cells
Ammonium tetrathiomolybdate (TM), a copper chelator, was purchased from Sigma-Aldrich (St. Louis, MO). 8-hydroxyquinoline-2-carboxaldehyde-thiosemicarbazide and 8-hydroxyquinoline-2-carboxaldehyde-4,4-dimethyl-3-thiosemicarbazide were purchased from Acros (New Jersy, NJ). The other reagents used in this study include matrigel matrix (corning, NY) and D-luciferin sodium (Gold Biotechnology, St. Louis, MO) were used without further purification. CuHQTS was synthesized and characterized as reported previously [13] . MSCV-LuciferaseEF1a-copGFP-T2A-Puro Pre-packaged Virus, a lentivirus containing a luciferase reporter gene, was purchased from System Biosciences (Palo Alto, CA). Prostate cancer cells was purchased from ATCC and cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) and Dulbecco's Modified Eagle Medium (DMEM, Sigma-Aldrich, St. Louis, MO) medium containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO) and 1% penicillin and streptomycin (Gibco, Auckland, NZ). PC-3 cell line carrying luciferase reporter gene (Luc-PC-3) was established by infection of PC-3 cells with MSCV-Luciferase-EF1a-copGFP-T2A-Puro Lentivirus in a protocol from the Vendor (System Biosciences, Palo Alto, CA).
Cell growth assay in vivo by bioluminescence imaging (BLI)
To evaluate prostate cancer cell growth in vivo, Luc-PC-3 cells (1 × 10 4 or 5 × 10 4 cells) suspended in 100 µL of 2:1 of medium and matrigel matrix were implanted subcutaneously in bilateral upper legs of athymic nu/nu mice (Taconic, Hudson, NY). Bioluminescence imaging (BLI) was performed in a method as previously reported [17] . Immediately after subcutaneous injection of D-luciferin (in 80 µL of PBS) in the back region, the mice implanted with Luc-PC-3 cells were placed on a warming pad in the imaging box and a series of images were acquired for 35 min with auto-exposure time (f stop = 1, stage setting = D) using an IVIS ® Spectrum system [Perkin-Elmer (Xenogen), Alameda, CA]. The mice were anesthetized by inhalation of 2% isoflurane (Butler animal health supply, Dublin, OH) with 2 L/min oxygen. Upon completion of imaging, elliptical regions of interests (ROIs) were drawn over cell implantation site on the mice and the luminescence signals in the ROI (total flux: p/s/ cm 2 /sr) were quantified using the Living Imaging, V 4.3.1 (PerkinElmer). The same ROIs were applied to all images acquired sequentially in a single imaging session for a given mouse. The total signal intensity was plotted against time after D-luciferin injection to generate a time-intensity curve. Peak time and peak signal were determined for assessment of signals from implanted Luc-PC-3 cells. The growth of Luc-PC-3 cells implanted in mice was monitored every week by BLI for 4 weeks. All procedures using rodents for this study were conducted in a small animal study protocol approved by Institutional Animal Care and Use Committee (IACUC) of the University of Texas Southwestern Medical Center, Dallas, TX, USA.
Cell growth inhibition assay in vivo by BLI
To test feasibility of assessing effect of anticancer agents on cell growth in vivo by BLI, the mice implanted with Lu-PC3 cells were orally administered with copper chelator TM (10, 20, 30 , and 40 µg/g body weight) daily, 
Tumor growth inhibition assay in vivo
To evaluate tumor growth inhibition activity of CuHQTS in vivo, athymic nu/nu mice were implanted with PC-3 cells (5 × 10 6 /injection) subcutaneously in the left and right flanks. Three days after implantation of PC-3 cells, the athymic nu/nu mice implanted with PC-3 cells were treated with intra-peritoneal injection of CuHQTS (15 µg/g body weight, dissolved in 100 μL saline containing 1% DMSO) every other day. Another group of athymic nu/nu mice implanted with PC-3 cells was treated with normal saline as a group of placebo control. Tumor growth in mice implanted with PC-3 cells was evaluated by visual assessment of tumor growth every 2 days for 2 weeks, and the size of tumor was measured with a ruler and recorded by length and width in centimeters. The volume of the tumor by a formula: V = 1/2ab 2 .
Statistical analysis
A paired T test was conducted for difference of luminescent signals from Luc-PC-3 cells in mice treated with CuHQTS and the luminescent signals from Luc-PC-3 cells in mice treated with normal saline. Difference of the PC-3 prostate xenograft tumor size in the mice treated with CuHQTS and the tumor size in the mice treated with normal saline (placebo control) was also tested by a paired Student's t test. A p value < 0.05 was considered statistically significant.
Results
Growth of Luc-PC-3 cells implanted in mice tracked by BLI
To determine whether growth of prostate cancer cells could be monitored with BLI, athymic nu/nu mice (n = 3) were implanted with Luc-PC3 cells (1 × 10 4 cells on the left leg and 5 × 10 4 cells on the right leg). Establishment and viability of Luc-PC3 cells implanted in mice were tested by BLI at 3 day post-implantation of the cells. Luciferase activity signals of Luc-PC3 cells carrying luciferase reporter gene were detected at implantation site on the mice, indicating successful stay and viability of Luc-PC3 cells. Growth of Luc-PC3 cells implanted in mice was tracked by BLI imaging every week for 4 weeks (Fig. 2) . Constant growth rate of Luc-PC3 cells was detected by BLI when 1 × 10 4 cells were implanted (Fig. 2a) . In contrast, variable growth rate of Luc-PC3 cells by BLI was observed when a larger number of Luc-PC3 cells (5 × 10 4 cells) were implanted to athymic nu/nu mice (Fig. 2b) . This suggested that implantation of a small number of 1 × 10 4 Luc-PC3 cells will allow accurate assessment of cell growth inhibition activity of anticancer 
Cell growth inhibition activity of TM on Luc-PC3 cells in vivo by BLI
Copper is required for proliferation of prostate cancer cells and proliferation of prostate cancer cells could be suppressed by treatment with a copper chelator such as TM. To test feasibility of using BLI to track the effects of anticancer agents on cell growth in vivo, athymic nu/nu mice implanted with Luc-PC-3 cells (1 × 10 4 luc-PC3 cells/site) were treated with oral administration of TM at a different dose (10, 20, 30, or 40 µg/g body weight). Suppressed growth of implanted Luc-PC-3 cells in the mice treated with TM was detected by BLI, compared with growth of Luc-PC-3 cells implanted in the control mice treated with normal saline (Fig. 3) /sr, p < 0.05). For unknown reasons, there was almost complete suppression of Luc-PC-3 cells growth when the mice were treated with 10, 20 or 40 µg TM/g body weight for 4 weeks. In contrast, incomplete suppression of Luc-PC-3 cell growth was detected by BLI when the mice implanted with Luc-PC-3 cells were treated with a dose of 30 µg/g body weight of TM for 4 weeks (Fig. 3) .
Cell growth inhibition activity of CuHQTS on Luc-PC-3 cells in vivo by BLI
Cell growth inhibition activity of CuHQTS on Luc-PC3 cells implanted in athymic nu/nu mice (n = 6) was assessed by BLI, based on the feasibility of using BLI to track cell growth inhibition activity of TM on prostate cancer cells in vivo. Initially, 1 × 10 5 cells were implanted in bilateral upper legs of athymic nu/nu mice. At 2 week post-implantation of Luc-PC3 cells, when luminescence signals of Luc-PC-3 cells reached about 5 × 10 7 p/s/cm 2 /sr, the mice implanted with Luc-PC3 cells were treated with intravenous injection of CuHQTS (15 µg/g body weight/100 µL of 0.1% DMSO), once every other day. On 6th day post-administration of CuHQTS, luminescence signals of Luc-PC-3 cells in mice treated with CuHQTS were found to be lower than the luminescence signals of Luc-PC-3 cells detected in the mice of placebo control (Figs. 3 4, 5 Fig 5) .
Tumor growth inhibition activity of CuHQTS on prostate cancer xenograft tumors in mice
Anti-prostate cancer activity of CuHQTS was further evaluated in vivo by assessment of effects of CuHQTS on growth of PC3 xenograft tumors in athymic nu/nu mice (n = 6, 3 in treatment group and 3 in placebo control. Starting 3-day post-implantation of PC-3 cells (5 × 10 6 cells/site), the mice implanted with PC-3 cells were treated with peritoneal injection of CuHQTS (15 µg/g body weight, dissolved in 100 μL saline containing 1% DMSO), once every other day. Growth of PC3 xenograft tumors in mice treated with CuHQTS was examined every day, and size of tumor was measured and compared with the PC3 xenograft tumors in mice of placebo control. Growth of PC3 tumors in mice treated with CuHQTS was suppressed, compared with growth of PC3 tumors in mice treated with normal saline of placebo control (Fig. 6) . 
Discussion
Copper complexes are promising new anticancer agents which may be used for treatment of cancer resistant to cisplatin [7] [8] [9] 18] . CuHQTS is a new copper complex with anticancer activity on prostate cancer cells in vitro [16] , in addition to potent anticancer activity on cisplatinresistant neuroblastoma cells [12] . In this study, we tested in vivo anti-prostate cancer activity of CuHQTS in mice for its potential application in treatment of metastatic prostate cancer refractory to anticancer drugs currently available. We attempted to establish BLI method to assess cell growth inhibition activity of CuHQTS on small number of cells implanted in mice for its potential use for treatment of minimal residual disease of metastatic prostate cancer, because the early treatment of minimal residual disease with CuHQTS may be more effective than treatment of late-stage, large solid tumor of prostate cancer. Bioluminescence imaging (BLI) is a useful optical imaging tool for detection of cancer metastasis and assessment of therapeutic effects of anticancer drugs in preclinical anticancer drug development using small animal models [19] [20] [21] [22] [23] . Using cancer cells expressing luciferase reporter gene, BLI could be used to monitor therapeutic effect of anticancer drugs such as topotecan, on cancer cells with high sensitivity [20, 21] . Although its low spatial resolution and depth sensitivity may limit its application in humans, BLI allows noninvasive, rapid preclinical testing of new anticancer drugs with high sensitivity and throughput [23] [24] [25] .
In this study, we attempted to establish animal model for tracking effects of anticancer drugs on growth of cancer cell carrying luciferase reporter gene implanted in mice by BLI. We observed constant increase of luminescence signals along with growth of Luc-PC3 cells in mice by BLI, after implantation of 1 × 10 4 Luc-PC-3 cells subcutaneously. The findings demonstrated feasibility of tracking growth of Luc-PC-3 cells in mice with BLI. To determine feasibility of using BLI to assess effects of anticancer drugs on growth of prostate cancer cells in vivo, we tested effects of TM, a copper chelator, on growth of Luc-PC3 cells implanted in mice by BLI. TM is a copper chelator with known anticancer activity against prostate cancer and many types of other tumors in vivo [26] [27] [28] [29] [30] . Molecular mechanism of anticancer activity of TM is not well defined, likely related to formation of a complex blocking the absorption of copper; the other one is formation of tripartite complex with copper and albumin in blood, blocking the cellular uptake of copper [26] . Marked decrease of luminescence signals of Luc-PC3 cells was detected in mice treated with TM, compared with luminescence signals of Luc-PC3 cells in mice of placebo control (Fig. 3) . These findings proved that BLI is a useful tool to track effect of anticancer drugs on growth of cancer cells implanted in mice. The luminescence signals of Luc-PC3 cells detected in the mice treated with 10 or 20 μg/g body weight of TM were lower than the luminescence signals of Luc-PC3 cells in the mice treated with 30 μg/g body weight of TM (Fig. 3) . The cause of this atypical dose response remained to be determined, which may be related to different microenvironment or other in vivo confounding factors present in the body of different mice.
Using BLI as a tool, we evaluated in vivo cell growth inhibition activity of CuHQTS on Luc-PC3 cells implanted in mice. Low luminescence signals of Luc-PC3 cells were visualized in the mice treated with CuHQTS, compared with the luminescence signals of Luc-PC3 cells in the mice treated with normal saline of placebo control (Figs. 4, 5) . In addition to cell growth inhibition demonstrated by BLI, the size of PC-3 xenograft tumors in the mice treated with CuHQTS was also smaller than the size of PC-3 xenograft tumors in the mice treated with normal saline (Fig. 6 ). These findings demonstrated in vivo anti-prostate cancer activity of CuHQTS, supporting further investigation of potential use of CuHQTS for treatment of metastatic prostate cancer in humans.
No death of mice was detected in the experiments of this study, until 1 month following intravenous injection of CuHQTS at a dose of 15 µg/g body weight contained in 100 µL of 0.1% DMSA. However, a significant body weight loss (> 10% body weight) was noted starting 3 days posttreatment with CuHQTS. Molecular mechanism of significant body weight loss in mice treated with CuHQTS remains to be elucidated, which may be related to toxic effect of thiosemicarbazone [31] or side effects of CuHQTS due to lack of cancer cell specificity. It is significant to continue synthesis of new thiosemicarbazone copper complexes with different molecular structures with selective cytotoxicity on prostate cancer cells. In addition to targeted delivery with polymerbased delivery vehicles [32, 33] and nano-particles [34, 35] , targeted delivery of CuHQTS to prostate cancer lesions in vivo with small molecules of high prostate-specific membrane antigen (PSMA)-binding affinity [36, 37] represents another promising approach to maximize anti-prostate cancer activity of CuHQTS and minimize side effects from nonspecific toxicity of CuHQTS on normal tissue or organs.
Conclusion
CuHQTS is a promising new anti-prostate cancer agent with strong anticancer activity in vivo, as demonstrated by cell growth inhibition activity in vivo demonstrated by BLI and tumor growth inhibition activity by tumor-sized measurement. BLI was successfully used for assessing cell growth inhibition activity of CuHQTS against Luc-PC3 prostate cancer cells implanted in mice, suggesting that BLI may be a useful tool for development of anticancer drugs targeting minimal residual disease in metastatic prostate cancer, and potentially other cancers.
